STA-5326

DRUG3 trials

Sponsors

Synta Pharmaceuticals Corp., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Common Variable ImmunodeficiencyCrohn's Disease

Phase 1

STA-5326 in Crohn's Disease Patients

CompletedNCT00088062

Synta Pharmaceuticals Corp.Crohn's Disease

Start: 2004-02-29End: 2004-11-30Target: 48Updated: 2005-06-24

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

CompletedNCT00263237

National Institute of Allergy and Infectious Diseases (NIAID)Common Variable Immunodeficiency

Start: 2005-12-02End: 2008-07-23Target: 10Updated: 2017-07-02

Phase 2

The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease

CompletedNCT00250198

National Institute of Allergy and Infectious Diseases (NIAID)Crohn's Disease

Start: 2005-11-03End: 2006-09-05Target: 12Updated: 2017-07-02